Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 8/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23133951 | 0.88 | CHRM3 (0.42) | CHRM3KCNH2KDM4EALDH1A1EPHX1 | |
| SCHEMBL3316196 | 0.85 | GNAI3 (0.53) | CHRM3KCNH2KDM4EALDH1A1PMP22 | |
| SCHEMBL1048005 | 0.79 | GPR183 (0.47) | CHRM3KCNH2KDM4EALDH1A1GNAI3 | |
| SCHEMBL23134625 | 0.78 | CHRM3 (0.40) | CHRM3KDM4EALDH1A1EPHX1EPHX2 | |
| SCHEMBL27097566 | 0.76 | GNAO1 (0.42) | CHRM3EPHX1EPHX2GNAI3GNAO1 | |
| SCHEMBL4236368 | 0.76 | GNAO1 (0.57) | CHRM3GNAI3GNAO1GNAI1 | |
| SCHEMBL27097459 | 0.76 | GNAO1 (0.42) | CHRM3EPHX1EPHX2GNAI3GNAO1 | |
| SCHEMBL5212568 | 0.76 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL5270128 | 0.76 | LIPC (0.42) | KDM4EALDH1A1EPHX2GNAI3GNAO1 | |
| SCHEMBL27762899 | 0.74 | CHRM3 (0.49) | CHRM3KCNH2EPHX1EPHX2GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | claimed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | CHRM3 168/4885KCNH2 1304/4885KDM4E 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.